BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34147845)

  • 1. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
    Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
    Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular-cholangiocarcinoma: An update.
    Beaufrère A; Calderaro J; Paradis V
    J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
    Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
    World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 8. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
    Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
    Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological aspects of mucinous cholangiocarcinoma: A single-center experience and systematic review.
    Laohawetwanit T; Klaikaew N
    Pathol Int; 2020 Sep; 70(9):661-670. PubMed ID: 32638458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
    Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
    Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
    JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
    Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
    J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
    Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
    J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
    Patil PA; Taddei T; Jain D; Zhang X
    Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
    Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
    J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.